New Tetanus Antibody Beats Standard Treatment in Chinese Trial at Modest Extra Cost

A trial-based economic evaluation published in Cost Effectiveness and Resource Allocation has found that siltartoxatug, a recombinant fully human anti-tetanus toxin monoclonal antibody, delivered substantially higher trial-defined immunological response rates than conventional human tetanus immunoglobulin (HTIG) for post-traumatic tetanus prophylaxis in Chinese adults, at an incremental drug cost of CNY 58.42 per patient.

Tetanus is a vaccine-preventable but potentially fatal post-traumatic infection that consumes substantial healthcare resources once disease develops. Passive immunization is recommended for patients with tetanus-prone wounds, and HTIG has long been the conventional passive immunizing product. However, dependence on human plasma may constrain supply and complicate blood-product handling and management. Siltartoxatug was developed as an alternative: an IgG1 monoclonal antibody that, in a phase III trial, produced earlier and more sustained anti-tetanus neutralizing antibody responses than HTIG.

The new study, led by Jianrun Zhang, Yuan Xiao and colleagues, conducted a short-term, two-arm cost-effectiveness analysis of siltartoxatug 10 mg versus HTIG 250 IU from a Chinese hospital pharmacy perspective. Rather than building a long-term model, the team combined drug acquisition prices with aggregate response data from the TNM002-301 phase III trial, making this a trial-based evaluation anchored in observed immunological outcomes.

Effectiveness was defined as the proportion of patients achieving the trial-prespecified increase from baseline in anti-tetanus neutralizing antibody titer of at least 0.01 IU/mL, measured at both 12 hours and 90 days after administration. The researchers reported the natural-unit incremental cost-effectiveness ratio (ICER), expressed as incremental drug cost per additional responder, alongside standardized drug-budget consequences per 1000 eligible patients, deterministic price scenarios, and a restricted probabilistic sensitivity analysis of response-rate uncertainty.

The per-dose costs were CNY 303.80 for siltartoxatug and CNY 245.38 for HTIG. Against those prices, the response-rate differences were striking: 42.2 percentage points at 12 hours, with 95.4 percent of siltartoxatug recipients achieving the defined titer increase versus 53.2 percent of HTIG recipients, and 81.4 percentage points at 90 days, with 91.5 percent versus 10.1 percent. The corresponding ICERs were CNY 138.4 per additional 12-hour responder and CNY 71.8 per additional 90-day responder.

In a standardized cohort of 1000 eligible patients, complete hypothetical replacement of HTIG with siltartoxatug would increase drug expenditure by CNY 58,420 while yielding approximately 422 additional 12-hour responders and 814 additional 90-day responders. The probabilistic sensitivity analysis, run over 10,000 simulations, produced median ICERs of CNY 139.1 (95 percent simulation interval 119.6 to 165.3) at 12 hours and CNY 72.2 (68.3 to 77.4) at 90 days, indicating that the ranking of the two products was stable under the explored response-rate uncertainty.

The authors are careful about what these numbers do and do not mean. At the evaluated prices, siltartoxatug produced higher trial-defined immunological response rates than HTIG for a modest incremental drug cost. But the results describe drug cost per additional pharmacodynamic responder and standardized budget consequences; they do not establish cost effectiveness against an accepted willingness-to-pay threshold, nor do they demonstrate reductions in clinical tetanus, hospitalization, mortality, or quality-adjusted life-years.

That limitation centers on the response measure itself. The increase in neutralizing antibody titer is mechanism-proximal and clinically interpretable for passive immunization, but it has not been validated as a surrogate for clinical tetanus incidence, hospitalization, mortality, or quality-adjusted life-years. In other words, a higher titer response rate is a plausible indicator of stronger passive protection, yet the economic analysis cannot claim that replacing HTIG would prevent more actual tetanus cases.

The scope of the analysis is also narrower than a full economic appraisal. It includes drug acquisition costs only, excluding other healthcare costs, and reports standardized replacement scenarios rather than a full budget impact analysis. The restricted probabilistic sensitivity analysis and an exploratory supplementary cost-effectiveness acceptability curve quantify conditional uncertainty but do not establish a national willingness-to-pay threshold for China or any other setting.

For decision makers, the practical takeaway is a transparent price-per-responder benchmark: at current evaluated prices, each additional patient achieving the 12-hour trial-defined immunological response costs CNY 138.4, and each additional patient achieving the 90-day response costs CNY 71.8. Whether that represents good value depends on judgments about how much weight to place on a pharmacodynamic endpoint, on supply considerations for plasma-derived HTIG, and on future research linking neutralizing antibody levels to clinical tetanus outcomes.

Subject of Research: Cost-effectiveness of siltartoxatug versus human tetanus immunoglobulin for post-traumatic tetanus prophylaxis in Chinese adults

Article Title: Short-term cost-effectiveness of siltartoxatug versus human tetanus immunoglobulin for post-traumatic tetanus prophylaxis in Chinese adults: a trial-based economic evaluation

Article References: Zhang, J., Xiao, Y., Huang, L., Wang, W., Hu, J., & Guo, W. (2026). Short-term cost-effectiveness of siltartoxatug versus human tetanus immunoglobulin for post-traumatic tetanus prophylaxis in Chinese adults: a trial-based economic evaluation. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-026-00841-x

Image Credits: AI Generated

DOI: 10.1186/s12962-026-00841-x

Keywords: siltartoxatug, human tetanus immunoglobulin, tetanus prophylaxis, cost-effectiveness, monoclonal antibody, phase III trial, China, ICER, neutralizing antibody, hospital pharmacy perspective, budget impact, HTIG